BRAIN Biotech AG publishes half year report with strong results remaining on solid growth path
Parent company, BRAIN Biotech AG today published its half year results, 6M 2022/2023, remaining on track to deliver on its full year financial targets and accelerates exciting growth strategy.
Highlights from BRAIN Biotech AG's announcement:
- H1 22/23 growth +16.8%, +8.2% organic growth
- Cash position a solid € 9.2 million
- Full ownership of core asset Biocatalysts Ltd achieved
BRAIN Biotech AG release strong H1 results paving the way for continued solid growth for the financial year. In the first six months of the 2022/23 financial year, the BRAIN Biotech Group generated revenue of € 27.2 million compared to € 23.3 million in the same period of the previous year, which represents growth of 16.8 %
For full information on the half-year results for BRAIN Biotech AG's three operating business segments click below.
“We are well on the way to execute on our ambitious fiscal year targets. Having gained full control of Biocatalysts Ltd builds the prerequisite to successfully execute our stated One-BioProducts strategy
